Blood markers may foretell brain fog after sepsis

NCT ID NCT07746050

Not yet recruiting Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study looks at whether certain proteins in the blood, which signal brain injury, can predict memory and thinking problems in people who survive sepsis or septic shock. Researchers will measure these biomarkers in 210 adults admitted to intensive care and check their cognitive function three months later using a memory test. The goal is to see if a simple blood test could help identify patients at higher risk for long-term cognitive issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Blood tests measuring brain injury biomarkers (NfL, tau, GFAP, and others)
What this could lead to: If certain biomarkers predict who will have memory or thinking problems after sepsis, doctors could identify high-risk patients early and target them for follow-up care or therapies.
What could go wrong: This is an observational study, so it cannot prove cause and effect. The biomarkers may not reliably predict cognitive outcomes, and results may not apply to all sepsis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

delirium infectious disease with sepsis postintensive care syndrome Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPSIS SEPTIC SHOCK

Contacts and locations

Locations

Hôpital Cochin - APHP Centre

Paris, Île-de-France Region, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.